Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
S Afr J Surg ; 62(2): 70, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38838127

RÉSUMÉ

SUMMARY: We present a previously healthy 13-year-old male, who sustained a handlebar injury after falling from his bicycle. The computerised tomography (CT) scan indicated a probable pancreatic neoplasm associated with a retroperitoneal haematoma which was, following resection, confirmed histologically to be a solid pseudopapillary neoplasm of the pancreas. These are rare tumours of the pancreas, especially in young males. The rarity of this neoplasm and the mechanism that led to its presentation make this an interesting and unique case.


Sujet(s)
Traumatismes de l'abdomen , Tumeurs du pancréas , Tomodensitométrie , Plaies non pénétrantes , Humains , Mâle , Tumeurs du pancréas/imagerie diagnostique , Tumeurs du pancréas/chirurgie , Tomodensitométrie/méthodes , Plaies non pénétrantes/imagerie diagnostique , Plaies non pénétrantes/complications , Plaies non pénétrantes/chirurgie , Adolescent , Traumatismes de l'abdomen/imagerie diagnostique , Traumatismes de l'abdomen/chirurgie , Traumatismes de l'abdomen/complications , Hématome/imagerie diagnostique , Hématome/étiologie , Hématome/chirurgie , Cyclisme/traumatismes
2.
BJOG ; 115(10): 1297-302, 2008 Sep.
Article de Anglais | MEDLINE | ID: mdl-18715416

RÉSUMÉ

OBJECTIVE: This study was designed to determine the safety of nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in a cohort of HIV-positive pregnant women. DESIGN: This was a prospective cohort study of HIV-positive pregnant women. POPULATION AND SETTING: All HIV-positive women treated with HAART during pregnancy from January 1997 to February 2004 at the British Columbia (BC) Women's Hospital in Vancouver, BC, Canada. METHODS: Demographic and clinical data were collected to compare antiretroviral drug toxicities in women treated antenatally with NVP-based or non-NVP-based HAART. Multivariate analyses were then used to investigate determinants of toxicity. RESULTS: From 1997 to 2004, 103 HIV-positive pregnant women received HAART. Equivalent numbers of women were initially treated with NVP-based (54%) and non-NVP-based (46%) HAART. The groups did not differ by clinical or demographic parameters and duration of HAART exposure was similar between groups. Toxicities necessitating treatment discontinuation were observed in 6 of 56 NVP-exposed women (2 cases each of grade 2, 3, and 4 toxicity) compared with 1 of 47 in the non-NVP-exposed women. First time use of NVP approached significance as a predictor for toxicity, with a toxicity rate of 12.5% (6/48) observed among those taking NVP for the first time (adjusted OR 2.68, 95% CI 0.49-14.6). CONCLUSION: Continuous NVP use in pregnancy resulted in a relatively higher rate of toxicity, and all cases of NVP toxicity occurred in women exposed to NVP for the first time during pregnancy.


Sujet(s)
Agents antiVIH/effets indésirables , Infections à VIH/traitement médicamenteux , Névirapine/effets indésirables , Complications infectieuses de la grossesse/traitement médicamenteux , Thérapie antirétrovirale hautement active/effets indésirables , Femelle , Humains , Analyse multifactorielle , Grossesse , Études prospectives
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE